Biogen (BIIB): Deutsche Bank Comments on Recent Weakness And Compares it to Celgene (CELG)
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/19/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- SanDisk stock rallies on AI optimism and Fed relief
RBC Capital Comments on Biogen (BIIB) and Tecfidera PML Case; Analyst Maintains Outperform Rating
October 22, 2014 1:27 PM EDTRBC Capital maintained an Outperform rating on Biogen (NASDAQ: BIIB) with a price target of $375. Analyst Michael J. Yee commented on today's decline, linking it to light Tecfidera results. He also tied the fall in part to the disclosure of a PML case for Tecfidera. After 4.5 years of... More
Baird Upgrades Biogen (BIIB) to Outperform
October 22, 2014 12:45 PM EDTBaird upgraded Biogen (NASDAQ: BIIB) from Neutral to Outperform with a price target of $382.00.
For an analyst ratings summary and ratings history on Biogen click here. For more ratings news on Biogen click here.
Shares of Biogen closed at $326.77 yesterday.
... MoreBiogen Idec (BIIB) Tops Q3 EPS by 31c; Boosts FY14 EPS Outlook
October 22, 2014 7:06 AM EDTBiogen Idec (NASDAQ: BIIB) reported Q3 EPS of $3.80, $0.31 better than the analyst estimate of $3.49. Revenue for the quarter came in at $2.5 billion versus the consensus estimate of $2.48 billion.
The third quarter was a period of significant achievement as we continued to make progress against our... More
